Yang Zha

Dr. Yang Zha


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YLYuxi Lin
Yuxi Lin
WWWeiqing Wang
Weiqing Wang
ZZZhenzhen Zhu
Zhenzhen Zhu
ASAodeng Surita
Aodeng Surita
LWLei Wang
Lei Wang
WLWei Lv
Wei Lv
(1) Background: Allergic rhinitis (AR) is a common disease in otolaryngology and novel biological therapies are required for clinical needs. To assess the tolerability of monoclonal antibodies, justifying their clinical applications, we presented a comprehensive safety profile of biologics in AR; (2) Methods: A systematic literature search was conducted following PRISMA guidelines for randomized clinical trials comparing monoclonal antibodies and placebo in AR. PubMed, Web of Science, Medline, and Cochrane were searched up until 9 January 2023. Among 3590 records in total, 12 studies with more than 2600 patients were included. Quality was assessed for all studies using Cochrane risk-of-bias tool for randomized trials, and subgrouped meta-analysis was performed; (3) Results: We accomplished an up-to-date literature overview and analysis on adverse events of monoclonal antibodies in AR. Total, common, severe, discontinuation-causing, and serious adverse events failed to reach statistical significance. Country was an essential factor for heterogeneity, and urticaria was the adverse event at highest risk (RR 2.81, 95% CI 0.79–9.95); (4) Conclusions: Monoclonal antibodies are considered well tolerated and relatively safe in patients with AR. The regions of patients and hypersensitive adverse reactions such as urticaria require a special caution in biological treatments in AR.

9 July 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
ASAodeng Surita
Aodeng Surita
TKTianhui Kang
Tianhui Kang
CCChuan Chen
Chuan Chen
HQHong Qiao
Hong Qiao
WLWei Lv
Wei Lv
YZYang Zha
Yang Zha
Background/Objectives: Allergic rhinitis (AR) is a highly prevalent chronic inflammatory disease of the upper airway characterized by immune dysregulation. This study aimed to systematically characterize the immunomodulatory landscape of AR and identify exploratory molecular and cellular features associated with disease-related immune remodeling. Methods: Public bulk transcriptomic datasets and single-cell RNA sequencing data were integrated to identify immunomodulatory-related differentially expressed genes (IMRDEGs), construct an immunomodulatory score (IM.Score), evaluate immune cell infiltration, and characterize cell-type composition and intercellular communication. Machine learning was used to derive an exploratory molecular signature, and L1000CDS2-based drug repositioning analysis was performed to identify in silico candidate compounds predicted to oppose AR-associated transcriptional signatures. Results: A total of 12 IMRDEGs were identified and used to construct the IM.Score, which was lower in AR samples relative to control samples. Immune infiltration analysis demonstrated that IM.Score stratification was associated with distinct immune microenvironmental profiles. Single-cell analysis revealed potential reductions in CD4+ central memory T cells, which represent an immune cellular alteration requiring further experimental verification, alongside attenuated intercellular communication involving this cell population. A six-gene exploratory molecular signature comprising NFKBIA, PDCD1, MYC, IFNG, FOXP3, and CD274 showed favorable performance in the training cohort (AUC = 0.992, 95% CI: 0.974–1.000) but failed to generalize in the external validation cohort (AUC = 0.500, 95% CI: 0.245–0.755), precluding clinical diagnostic interpretation at this stage. Drug repositioning analysis identified candidate compounds, including narciclasine and BRD-K91370081, with the potential to reverse AR-associated transcriptional alterations. Conclusions: This integrative multi-omics analysis identifies coordinated molecular, cellular, and communication-level immune alterations in AR. The IM.Score, altered CD4+ central memory T-cell abundance, and six-gene exploratory molecular signature may be regarded as hypothesis-generating candidate clues pending further experimental and clinical validation.

Verified
Journal Article
Open access
PDF file
YLYuzhuo Liu
Yuzhuo Liu
JHJinbo Han
Jinbo Han
XWXiaowei Wang
Xiaowei Wang
WWWeiqing Wang
Weiqing Wang
LWLei Wang
Lei Wang
ZZZhenzhen Zhu
Zhenzhen Zhu
Allergic rhinitis (AR) and chronic rhinosinusitis with nasal polyps (CRSwNP) share overlapping inflammatory mechanisms while retaining distinct disease biology. Although lipid metabolism is increasingly implicated in airway inflammation, the nasal fluid lipidomic landscape across AR and CRSwNP and its relationship to local eosinophilic inflammation and clinical burden remain incompletely understood. We performed widely targeted liquid chromatography–tandem mass spectrometry (LC-MS/MS) lipidomics on nasal fluid from 73 participants, including 22 controls, 23 patients with AR, and 28 patients with CRSwNP. Group differences were evaluated using multivariate analysis and models adjusted for age, sex, and smoking status, followed by trajectory clustering and residual-correlation network analysis. Within CRSwNP, adjusted models were used to assess lipid associations with tissue eosinophilia, the 22-item Sinonasal Outcome Test (SNOT-22), overall visual analog scale (VAS), and Lund–Mackay computed tomography score. Lipid subclass patterns were examined by ranked enrichment and focused subclass score analyses. AR was characterized mainly by higher relative abundances of TG species, whereas CRSwNP showed broader increases involving triacylglycerol species, plasmalogen phosphatidylethanolamines, and lysophospholipids. Exploratory clustering of 147 lipids showing nominally significant differences (p < 0.05) in at least one covariate-adjusted pairwise group comparison yielded four modules with differing biochemical compositions, although the partition was sensitive to the input lipid set. Among these, the diacylglycerol–lysophosphatidic acid-related module displayed strong internal network connectivity, suggesting coordinated variation within the identified module. Within CRSwNP, ranked analysis of lipid associations with tissue eosinophilia showed negative enrichment of plasmalogen phosphatidylethanolamine, sphingomyelin, and ether-linked lysophosphatidylcholine, and positive enrichment of glycerolipid and acylcarnitine subclasses. Clinical burden showed only partial overlap with this pattern: plasmalogen phosphatidylethanolamine was inversely associated with both tissue eosinophilia and patient-reported symptom burden, whereas conventional lysophosphatidylcholine showed stronger positive associations with symptomatic and radiographic burden. These findings suggest distinct and coordinated nasal fluid lipidomic features associated with the upper-airway inflammatory phenotype, local eosinophilic inflammation, and clinical disease burden.